Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

88 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Raymond E, et al. Among authors: horsch d. N Engl J Med. 2011 Feb 10;364(6):501-13. doi: 10.1056/NEJMoa1003825. N Engl J Med. 2011. PMID: 21306237 Clinical Trial.
Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.
Hörsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Miederer M, Schreckenberger M, Krause BJ, Bengel FM, Bartenstein P, Biersack HJ, Pöpperl G, Baum RP. Hörsch D, et al. Eur J Cancer. 2016 May;58:41-51. doi: 10.1016/j.ejca.2016.01.009. Epub 2016 Mar 2. Eur J Cancer. 2016. PMID: 26943056
Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.
Vinik A, Bottomley A, Korytowsky B, Bang YJ, Raoul JL, Valle JW, Metrakos P, Hörsch D, Mundayat R, Reisman A, Wang Z, Chao RC, Raymond E. Vinik A, et al. Among authors: horsch d. Target Oncol. 2016 Dec;11(6):815-824. doi: 10.1007/s11523-016-0462-5. Target Oncol. 2016. PMID: 27924459 Clinical Trial.
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Öberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group. Pavel ME, et al. Among authors: horsch d. Lancet. 2011 Dec 10;378(9808):2005-2012. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25. Lancet. 2011. PMID: 22119496 Clinical Trial.
Pancreatic neuroendocrine neoplasms.
Hörsch D, Bert T, Schrader J, Hommann M, Kaemmerer D, Petrovitch A, Zaknun J, Baum RP. Hörsch D, et al. Minerva Gastroenterol Dietol. 2012 Dec;58(4):401-26. Minerva Gastroenterol Dietol. 2012. PMID: 23207615 Review.
Current treatment options for neuroendocrine tumors.
Hörsch D, Grabowski P, Schneider CP, Petrovitch A, Kaemmerer D, Hommann M, Baum RP. Hörsch D, et al. Drugs Today (Barc). 2011 Oct;47(10):773-86. doi: 10.1358/dot.2011.47.10.1673555. Drugs Today (Barc). 2011. PMID: 22076492 Review.
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. Kulke MH, et al. Among authors: horsch d. J Clin Oncol. 2017 Jan;35(1):14-23. doi: 10.1200/JCO.2016.69.2780. Epub 2016 Oct 28. J Clin Oncol. 2017. PMID: 27918724 Clinical Trial.
[Neuroendocrine neoplasms of the breast].
Anlauf M, Neumann M, Bomberg S, Luczak K, Heikaus S, Gustmann C, Antke C, Ezziddin S, Fottner C, Pavel M, Pape UF, Rinke A, Lahner H, Schott M, Cremer B, Hörsch D, Baum RP, Groh U, Alkatout I, Rudlowski C, Scheler P, Zirbes TK, Hoffmann J, Fehm T, Gabbert HE, Baldus SE. Anlauf M, et al. Among authors: horsch d. Pathologe. 2015 May;36(3):261-70. doi: 10.1007/s00292-015-0024-0. Pathologe. 2015. PMID: 25986886 Review. German.
88 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page